Combination of Electrochemotherapy with Radiotherapy: A Comprehensive, Systematic, PRISMA-Compliant Review of Efficacy and Potential Radiosensitizing Effects in Tumor Control.
electrochemotherapy
electroporation
radiosensitivity
radiotherapy
systematic review
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
11
10
2023
revised:
27
10
2023
accepted:
31
10
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
Radiotherapy (RT) and electrochemotherapy (ECT) are established local treatments for cancer. While effective, both therapies have limitations, especially in treating bulky and poorly oxygenated tumors. ECT has emerged as a promising palliative treatment, raising interest in exploring its combination with RT to enhance tumor response. However, the potential benefits and challenges of combining these treatments remain unclear. A systematic review was conducted following PRISMA guidelines. PubMed, Scopus, and Cochrane libraries were searched. Studies were screened and selected based on predefined inclusion and exclusion criteria. Ten studies were included, comprising in vitro and in vivo experiments. Different tumor types were treated with ECT alone or in combination with RT. ECT plus RT demonstrated superior tumor response compared to that under single therapies or other combinations, regardless of the cytotoxic agent and RT dose. However, no study demonstrated a clear superadditive effect in cell survival curves, suggesting inconclusive evidence of specific ECT-induced radiosensitization. Toxicity data were limited. In conclusion, the combination of ECT and RT consistently improved tumor response compared to that with individual therapies, supporting the potential benefit of their combination. However, evidence for a specific ECT-induced radiosensitization effect is currently lacking. Additional investigations are necessary to elucidate the potential benefits of this combination therapy.
Identifiants
pubmed: 37999139
pii: curroncol30110719
doi: 10.3390/curroncol30110719
pmc: PMC10670517
doi:
Substances chimiques
Radiation-Sensitizing Agents
0
Antineoplastic Agents
0
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9895-9905Références
Int J Nanomedicine. 2021 Feb 12;16:1083-1102
pubmed: 33603370
Biochem Pharmacol. 1988 Dec 15;37(24):4727-33
pubmed: 2462423
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):75-82
pubmed: 28258897
Curr Drug Targets. 2017 Nov 30;18(16):1893-1903
pubmed: 28641523
Radiol Oncol. 2012 Sep;46(3):226-32
pubmed: 23077461
Cancers (Basel). 2023 Feb 22;15(5):
pubmed: 36900190
Bioelectrochemistry. 2018 Feb;119:161-171
pubmed: 29024870
Future Oncol. 2014 Apr;10(5):877-90
pubmed: 24799067
Radiat Res. 2004 Aug;162(2):185-93
pubmed: 15387146
Med Sci Monit. 2021 Nov 03;27:e934116
pubmed: 34728593
Radiat Res. 2009 Dec;172(6):677-85
pubmed: 19929414
J Exp Clin Cancer Res. 2021 Jun 21;40(1):197
pubmed: 34154610
Cryobiology. 1997 Aug;35(1):70-8
pubmed: 9302769
Radiother Oncol. 1998 Feb;46(2):135-46
pubmed: 9510041
Anticancer Res. 2003 Jan-Feb;23(1A):275-81
pubmed: 12680224
Cancer Treat Rev. 1974 Mar;1(1):15-26
pubmed: 4143475
Asian Pac J Cancer Prev. 2018 May 26;19(5):1259-1262
pubmed: 29801410
J Environ Pathol Toxicol Oncol. 2006;25(4):625-32
pubmed: 17341203
J Environ Pathol Toxicol Oncol. 2005;24(4):291-8
pubmed: 16393122
BMC Cancer. 2005 Sep 16;5:115
pubmed: 16168056
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):1037-41
pubmed: 10705027
Clinics (Sao Paulo). 2018 Dec 10;73(suppl 1):e557s
pubmed: 30540123
Ultrasound Med Biol. 2017 Feb;43(2):398-411
pubmed: 27780661